Background Denosumab is a fully human monoclonal antibody to the receptor activator of
nuclear factor-κB ligand (RANKL) that blocks its binding to RANK, inhibiting the development …

Background A single infusion of intravenous zoledronic acid decreases bone turnover and
improves bone density at 12 months in postmenopausal women with osteoporosis. We …

… occurred in the study by Reid 199321 22 or Bonnick 2007,30 no strokes occurred in the
study by Reid 2008,33 and no deaths occurred in the study by Reid 1993.Data on composite …

This work provides a systematic review of the literature from January 2003 to April 2014
pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of the …

… Mark J Bolland, senior research fellow,1 Andrew Grey, associate professor,1 Alison
Avenell, clinical research fellow,2 Greg D Gamble, research fellow,1 Ian R Reid, professor of …

Background Bisphosphonates are effective agents for the management of osteoporosis.
Their low bioavailability and low potency necessitate frequent administration on an empty …

Objective To determine the effect of calcium supplementation on myocardial infarction,
stroke, and sudden death in healthy postmenopausal women. Design Randomised, placebo …

Body weight impacts on both bone turnover and bone density, and is therefore an important
risk factor for vertebral and hip fractures, ranking in importance alongside that of age. The …

Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal
women with osteoporosis. To investigate long‐term effects of ZOL on bone mineral density (…

Background Findings from recent meta-analyses of vitamin D supplementation without co-administration
of calcium have not shown fracture prevention, possibly because of insufficient …